An open-label, multi-center, dose-escalation Phase Ib study to determine the recommended phase 2 dose of APN401 in patients with advanced solid tumors

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Invios GmbH

Enrolment target

12

Start

24 Jul 2023

Age 18 Years to any · Sex: All

• —

  Austria